Table 3.

Total exposure to systemic corticosteroids during control and exposure intervals.

	mg per person-y		P-valuea
	Before biologic use (Control interval)	During antibody use (Exposure interval)
All patients (n = 355; before biologic use: 355.0 person-y, during biologic use: 447.9 person-y)	600.0 [90.0–1713.0]	163.6 [0.0–1010.1]	<.001
Patients with regular OCS (n = 72; before biologic use: 72.0 person-y, during biologic use: 98.9 person-y)	2310.0 [1381.0–3924.0]	830.8 [248.0–3052.6]	.013
Omalizumab (n = 119; before biologic use: 119.0 person-y, during biologic use: 188.3 person-y)	721.2 [180.0–1927.5]	355.6 [23.7–1388.7]	.055
Mepolizumab (n = 82; before biologic use: 82.0 person-y, during biologic use: 120.3 person-y)	936.1 [340.4–1781.1]	392.8 [21.3–1256.7]	.008
Benralizumab (n = 69; before biologic use: 69.0 person-y, during biologic use: 71.3 person-y)	1024.0 [224.0–2328.0]	219.5 [0.0–1047.6]	<.001
Dupilumab (n = 85; before biologic use: 85.0 person-y, during biologic use: 68.0 person-y)	75.0 [0.0–375.0]	0.0 [0.0–23.8]	<.001

OCS, oral corticosteroids.

The cumulative dosage of systemic corticosteroids is indicated as the prednisolone equivalent.

^aPaired Wilcoxon signed-rank test